Fenoverine
Trade name: spasmopriv
Small moleculeexperimental
Clinical trial activity
1 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
0
Phase 2
0
Phase 3
0
Phase 4
1
Earliest trial started Dec 1, 2011 (NCT01507922)
Timeline
No events for the selected filters.
Indications
Approved for
Studied for
Mechanism of action
Chemistry & pharmacology
Loading structure…
SMILES
O=C(CN1CCN(Cc2ccc3c(c2)OCO3)CC1)N1c2ccccc2Sc2ccccc21- Mol. weight
- 459.57 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Achiral Molecule
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL1512949 ↗
Also known as
- 10-((4-piperonyl-1-piperazinyl)acetyl)phenothiazine
- fenoverine
- fenoverine
- fenoverine
- fenoverine
- fenoverine
- fenoverine
- fenoverine
- fenoverine
- spasmopriv
- spasmopriv
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT01507922 | Phase 4 | Dec 1, 2011 | Bukwang Pharmaceutical, Korea University |
Showing 1 of 1 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Bukwang Pharmaceutical | For profit | 1 | 1 | 1 | 2011 |
| Korea University | Academic/Hospital | 1 | 0 | 1 | 2011 |
2 organizations
Page 1 / 1